GSK Arexvy protects from RSV over three full seasons
GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial ...
Taiwan News10h
Dysmenorrhea Treatment Market Insights, Advances in Pain Management and Women’s Health, 2024 to 2033
The global dysmenorrhea treatment market, valued at approximately USD 5,937.8 million in 2022, is projected to reach USD 6,324.5 million in 2023 and USD 13,106.5 million by 2032, exhibiting a CAGR of ...
Taiwan News11h
Cough Remedies Market Outlook, Innovations and Trends in Respiratory Health, 2024 to 2032
The Global Cough Remedies Market is valued at approximately USD 7.83 billion in 2023 and is projected to grow with a steady CAGR of 3.9% over the forecast period 2024-2032. Request To Download Free ...
Wall Street indexes slip with interest rates, Middle East in focus
Further dampening sentiment on Monday was an order from a U.S. judge for market heavyweight Alphabet's Google to overhaul its ...
One of science’s greatest achievements: how the rapid development of COVID vaccines prepares us for future pandemics
One of the cornerstones of being prepared for the next pandemic is being in the best position possible to design and deploy a ...